Successful treatment of advanced alveolar soft part sarcoma with camrelizumab combined with apatinib: A case report

Abstract

Alveolar soft part sarcoma (ASPS) is a rare and highly malignant mesenchymal tumor that primarily affects adolescents and young adults. ASPS is characterized by a slow growth rate, high metastatic potential, and resistance to conventional therapies. The emergence of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced malignancies, improving the objective response rate (ORR) and prolonging patient survival. The combination of immunotherapy with targeted therapies can overcome resistance to treatment with ICIs alone. Although substantial progress has been made in various solid tumors, the clinical relevance of ICIs, used alone or in combination with other therapies, in patients with ASPS remains unclear. This is a case report of a 32-year-old man who was diagnosed with advanced ASPS. After 8 months of anlotinib treatment, the patient’s disease progressed and new cerebellar metastases were detected. Radiotherapy was administered in addition to camrelizumab combined with apatinib to treat the brain metastases. The patient achieved partial remission (46%) after 3 months of treatment and did not present any severe side effects. This is the first reported case of the successful treatment of advanced ASPS with camrelizumab combined with apatinib. This case supports the use of a novel treatment regimen for patients with inoperable ASPS or ASPS that is resistant to conventional therapies.